| Serial Number | 98081053 |
| Word Mark | MULTABODY |
| Filing Date | Wednesday, July 12, 2023 |
| Status | 686 - PUBLISHED FOR OPPOSITION |
| Status Date | Tuesday, April 8, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, April 8, 2025 |
| Goods and Services | Pharmaceutical and veterinary preparations, namely, pharmaceutical preparations based on antibodies, bi and multispecific antibodies as well as fragments, including monovalent antibodies, derivatives or conjugates of any of these for use with regard to the treatment of cancer, infectious, immune, autoimmune, inflammatory, neurodegenerative and cardiovascular diseases; pharmaceutical preparations based on human monoclonal antibodies for the treatment of cancer, AIDS (acquired immune deficiency syndrome) and other infectious diseases, immune and autoimmune diseases, inflammatory diseases and cardiovascular diseases |
| Pseudo Mark | MULTA BODY |
| Goods and Services | Chemical, biochemical, biological, and biotechnological, preparations, namely, antibodies, bi- and multispecific antibodies as well as fragments, monovalent antibodies, derivatives of conjugates of any of these for in vitro and in vivo scientific and industrial research and development with regard to diseases; biochemicals, namely, monoclonal antibodies for in vivo or in vitro scientific research and development regarding cancer, AIDS (acquired immune deficiency syndrome), and other infectious diseases, immune and autoimmune diseases, inflammatory diseases and cardiovascular diseases |
| Goods and Services | Licensing of intellectual property in the field of medicine |
| Goods and Services | Medical, scientific and biological research; research in antibodies, bi and multispecific antibodies or fragments, monovalent antibodies, derivatives or conjugates of any of these and development services of new pharmaceutical products based on antibodies, bi and multispecific antibodies or fragments, monovalent antibodies, derivatives or conjugates of any of these; chemical analysis; development of pharmaceutical preparations and medicines containing antibodies, bi- and multispecific antibodies or fragments, monovalent antibodies, derivatives or conjugates of any of these; medical and scientific research, namely, biological scientific research into human monoclonal antibodies and development of pharmaceutical products based on human monoclonal antibodies for the treatment of cancer, AIDS (acquired immune deficiency syndrome) and other infectious diseases, immune and autoimmune diseases, inflammatory diseases and cardiovascular diseases |
| International Class | 001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. |
| US Class Codes | 001, 005, 006, 010, 026, 046 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, August 10, 2023 |
| Primary Code | 001 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, August 10, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, August 10, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 045 - Legal services; security services for the protection of property and individuals; personal and social services rendered by others to meet the needs of individuals. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, August 10, 2023 |
| Primary Code | 045 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Radiant Biotherapeutics |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Toronto, ON M5G0A4 CA |
| Party Name | Radiant Biotherapeutics |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Toronto, ON M5G0A4 CA |
| Event Date | Event Description |
| Saturday, July 15, 2023 | NEW APPLICATION ENTERED |
| Thursday, August 10, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Wednesday, March 20, 2024 | ASSIGNED TO EXAMINER |
| Monday, April 22, 2024 | NON-FINAL ACTION E-MAILED |
| Monday, April 22, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Monday, April 22, 2024 | NON-FINAL ACTION WRITTEN |
| Wednesday, July 10, 2024 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Tuesday, October 22, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, October 22, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, July 10, 2024 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| Tuesday, October 22, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, March 13, 2025 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, April 2, 2025 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, April 8, 2025 | PUBLISHED FOR OPPOSITION |
| Tuesday, April 8, 2025 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |